Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Building a scalable, multilevel healthcare pipeline program through structured mentoring families: perceptions and outcomes from two cohorts.

Journal of the National Medical Association·2026
Same author

Corrigendum to "A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome" [Multiple Sclerosis and Related Disorders 112 (2026) 107312].

Multiple sclerosis and related disorders·2026
Same author

Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.

Journal of neurology·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome.

Multiple sclerosis and related disorders·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

相关实验视频

Updated: Jun 26, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K

疾病修饰疗法与多发性硬化症中信息处理速度之间的关联

Albert Aboseif1, Moein Amin2, James Bena1

  • 1From the Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

International journal of MS care
|May 20, 2024
PubMed
概括

疾病修饰疗法 (DMT) 的使用和强度在两年内对多发性硬化症 (MS) 患者的认知处理速度没有显著影响. 需要进一步的研究来证实这些关于MS认知功能的发现.

关键词:
认知障碍是一种认知障碍.改变疾病的疗法.多发性硬化症多发性硬化症处理速度 处理速度.

更多相关视频

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

相关实验视频

Last Updated: Jun 26, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.0K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

科学领域:

  • 神经学 神经学
  • 神经免疫学 神经免疫学
  • 认知神经科学 认知神经科学

背景情况:

  • 认知障碍是多发性硬化症 (MS) 的一个普遍问题.
  • 处理速度 (PS) 缺陷在MS中很常见,并作为认知障碍的关键指标.
  • 评估疾病修饰疗法 (DMT) 对认知功能的影响对于MS管理至关重要.

研究的目的:

  • 调查疾病修饰疗法 (DMT) 使用及其强度与处理速度的纵向变化之间的关联.
  • 评估DMT状态 (在治疗中或停止治疗) 和疗效 (高或低/中等) 是否会影响MS患者的认知处理速度.

主要方法:

  • 对处理速度测试 (PST) 评分的回顾性分析,来自至少两次评估的个人.
  • 两年多使用DMT和两年多不使用DMT的患者之间的纵向PST得分的比较.
  • 使用多变量逻辑回归来控制混因素的倾向得分调整.

主要成果:

  • 这项研究包括642人,539人使用DMT,103人不使用DMT.
  • 经过多种因素的调整后,DMT状态和强度都没有显著预测PST得分的纵向变化.
  • 对于DMT和非DMT组,平均监测持续时间约为1.8-1.9年.

结论:

  • 在两年内,DMT状态和强度并不是认知处理速度的显著预测因素.
  • 这些发现表明,目前的DMT可能不会显著改变MS的认知处理速度轨迹.
  • 建议进行前性研究,以进一步验证这些结果,并探索其他影响MS认知功能的因素.